Reporting on circulating tumor DNA monitoring in metastatic cancer-From clinical validity to clinical utility

Caroline Brenner Thomsen; Amanda Dandanell Juul; Anna Cecilie Lefèvre; Christina Glismand Truelsen; Edina Dizdarevic; Heidi Ryssel; Ina Mathilde Kjaer; Karen Lycke Wind; Louise Bach Callesen; Louise Faaborg Larsen; Malene Støchkel Frank; Rikke Fredslund Andersen; Karen-Lise Garm Spindler; Anders Jakobsen

doi:10.1002/cncr.34168

Reporting on circulating tumor DNA monitoring in metastatic cancer-From clinical validity to clinical utility

Cancer. 2022 Jun 1;128(11):2052-2057. doi: 10.1002/cncr.34168. Epub 2022 Mar 18.

Authors

Caroline Brenner Thomsen^{1

2}, Amanda Dandanell Juul³, Anna Cecilie Lefèvre^{4

5}, Christina Glismand Truelsen^{4

5}, Edina Dizdarevic^{1

2}, Heidi Ryssel⁶, Ina Mathilde Kjaer^{2

7}, Karen Lycke Wind^{4

5}, Louise Bach Callesen^{4

5}, Louise Faaborg Larsen², Malene Støchkel Frank^{8

9}, Rikke Fredslund Andersen¹, Karen-Lise Garm Spindler^{4

5}, Anders Jakobsen^{1

2}

Affiliations

¹ Danish Colorectal Cancer Center South, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
² Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
³ Odense Respiratory Research Unit, Odense University Hospital, Odense, Denmark.
⁴ Experimental Clinical Oncology, Department of Oncology, Arhus University Hospital, Aarhus, Denmark.
⁵ Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
⁶ Department of Clinical Physiology, PET and Nuclear Medicine, Rigshospitalet, Copenhagen, Denmark.
⁷ Department of Biochemistry and Immunology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
⁸ Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark.
⁹ Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Abstract

This commentary attempts to discuss the required standardization of circulating tumor DNA (ctDNA) analyses and thereby improve the clinical validity of ctDNA monitoring in the metastatic setting of solid tumors.

Keywords: circulating tumor DNA (ctDNA); clinical utility; metastatic cancer; monitoring; reporting on circulating tumor DNA; standardization.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / genetics
Circulating Tumor DNA* / genetics
Humans
Mutation
Neoplasms* / genetics
Neoplasms, Second Primary*

Substances

Biomarkers, Tumor
Circulating Tumor DNA